Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study

Psychological Medicine

Volumn 46, Issue 2, 2016, Pages 357-366

  Kim, E ^a   Howes, O D ^b,c   Park, J W ^d   Kim, S N ^d   Shin, S A ^e   Kim, B H ^f   Turkheimer, F E ^c   Lee, Y S ^d   Kwon, J S ^d,g  

^a Seoul National University Bundang Hospital   (South Korea)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Seoul National University College of Medicine   (South Korea)

^e Seoul National University   (South Korea)

^f Kyung Hee University   (South Korea)

^g Seoul National University   (South Korea)

Author keywords

Anxiety disorder; molecular imaging; obsessive compulsive disorder; serotonin transporter; SSRI

Indexed keywords

BENZYLAMINE DERIVATIVE; CARBON; CITALOPRAM; N,N-DIMETHYL-2-(2-AMINO-4-CYANOPHENYLTHIO)BENZYLAMINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ADULT; BRAIN; CASE CONTROL STUDY; CAUDATE NUCLEUS; DIAGNOSTIC IMAGING; FEMALE; HUMAN; MALE; METABOLISM; OBSESSIVE-COMPULSIVE DISORDER; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; THALAMUS; YOUNG ADULT;

ADULT; BENZYLAMINES; BRAIN; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; CITALOPRAM; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; THALAMUS; YOUNG ADULT;

EID: 84943804968     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291715001865     Document Type: Article

References (47)

1. Aylward EH, Harris GJ, Hoehn-Saric R, Barta PE, Machlin SR, Pearlson GD (1996). Normal caudate nucleus in obsessive-compulsive disorder assessed by quantitative neuroimaging. Archives of General Psychiatry 53, 577-584.
2. Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083-1152.
3. Baumgarten HG, Grozdanovic Z (1998). Role of serotonin in obsessive-compulsive disorder. British Journal of Psychiatry 35, (Suppl.), 13-20.
4. Bech P, Lonn SL, Overo KF (2010). Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder. Journal of Clinical Psychiatry 71, 121-129.
5. Bel N, Artigas F (1992). Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. European Journal of Pharmacology 229, 101-103.
6. Cadeddu R, Ibba M, Sadile A, Carboni E (2014). Antidepressants share the ability to increase catecholamine output in the bed nucleus of stria terminalis: a possible role in antidepressant therapy? Psychopharmacology 231, 1925-1933.
7. Collu M, Poggiu AS, Devoto P, Serra G (1997). Behavioural sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine-treated rats. European Journal of Pharmacology 322, 123-127.
8. Dziedzicka-Wasylewska M, Rogoz Z, Skuza G, Dlaboga D, Maj J (2002). Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D(2)/D(3) receptors. Behavioural Pharmacology 13, 127-138.
9. Egerton A, Mehta MA, Montgomery AJ, Lappin JM, Howes OD, Reeves SJ, Cunningham VJ, Grasby PM (2009). The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neuroscience and Biobehavioral Reviews 33, 1109-1132.
10. Fernandez Cordoba E, Lopez-Ibor Alino J (1967). Use of monochlorimipramine in psychiatric patients who are resistant to other therapy. Actas Luso-Espanolas de Neurologia y Psiquiatria 26, 119-147.
11. Fineberg NA, Tonnoir B, Lemming O, Stein DJ (2007). Escitalopram prevents relapse of obsessive-compulsive disorder. European Neuropsychopharmacology 17, 430-439.
12. Gartside SE, Umbers V, Hajos M, Sharp T (1995). Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. British Journal of Pharmacology 115, 1064-1070.
13. Giovacchini G, Lang L, Ma Y, Herscovitch P, Eckelman WC, Carson RE (2005). Differential effects of paroxetine on raphe and cortical 5-HT1A binding: a PET study in monkeys. Neuroimage 28, 238-248.
14. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry 46, 1006-1011.
15. Hajos-Korcsok E, McTavish SF, Sharp T (2000). Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. European Journal of Pharmacology 407, 101-107.
16. Hesse S, Muller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, Sabri O, Stengler-Wenzke K (2005). Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Research 140, 63-72.
17. Hesse S, Stengler K, Regenthal R, Patt M, Becker GA, Franke A, Knupfer H, Meyer PM, Luthardt J, Jahn I, Lobsien D, Heinke W, Brust P, Hegerl U, Sabri O (2011). The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. International Journal of Neuropsychopharmacology 14, 606-617.
18. Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, Suhara T, Suzuki K, Innis RB, Carson RE (2003). Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. Journal of Cerebral Blood Flow and Metabolism 23, 1096-1112.
19. Innis R, Baldwin R, Sybirska E, Zea Y, Laruelle M, al-Tikriti M, Charney D, Zoghbi S, Smith E, Wisniewski G, Hoffer P, Wang S, Milius R, Neumeyer J (1991). Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [123I]CIT. European Journal of Pharmacology 200, 369-370.
20. Kang KW, Lee DS, Cho JH, Lee JS, Yeo JS, Lee SK, Chung JK, Lee MC (2001). Quantification of F-18 FDG PET images in temporal lobe epilepsy patients using probabilistic brain atlas. Neuroimage 14, 1-6.
21. Karno M, Golding JM, Sorenson SB, Burnam MA (1988). The epidemiology of obsessive-compulsive disorder in five US communities. Archives of General Psychiatry 45, 1094-1099.
22. Kim E, Howes OD, Yu KS, Jeong JM, Lee JS, Jang IJ, Shin SG, Kapur S, Kwon JS (2011). Calculating occupancy when one does not have baseline: a comparison of different options. Journal of Cerebral Blood Flow and Metabolism 31, 1760-1767.
23. Kwon JS, Jang JH, Choi JS, Kang DH (2009). Neuroimaging in obsessive-compulsive disorder. Expert Review of Neurotherapeutics 9, 255-269.
24. Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL, Milius RA, Wang S, Smith EO, Roth RH, Charney DS, Hoffer PB, Innis RB (1993). SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13, 295-309.
25. Lee JS, Lee DS (2005). Analysis of functional brain images using population-based probabilistic atlas. Current Medical Imaging Reviews 1, 81-87.
26. Malagie I, Trillat AC, Jacquot C, Gardier AM (1995). Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. European Journal of Pharmacology 286, 213-217.
27. Matsumoto R, Ichise M, Ito H, Ando T, Takahashi H, Ikoma Y, Kosaka J, Arakawa R, Fujimura Y, Ota M, Takano A, Fukui K, Nakayama K, Suhara T (2010). Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study. Neuroimage 49, 121-126.
28. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry 51, 302-308.
29. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C] DASB positron emission tomography study. American Journal of Psychiatry 161, 826-835.
30. Neumeyer JL, Tamagnan G, Wang S, Gao Y, Milius RA, Kula NS, Baldessarini RJ (1996). N-substituted analogs of 2 beta-carbomethoxy-3 beta- (4?-iodophenyl)tropane (beta-CIT) with selective affinity to dopamine or serotonin transporters in rat forebrain. Journal of Medicinal Chemistry 39, 543-548.
31. Nord M, Finnema SJ, Halldin C, Farde L (2013). Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. International Journal of Neuropsychopharmacology 16, 1577-1586.
32. Overbeek T, Schruers K, Vermetten E, Griez E (2002). Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. Journal of Clinical Psychiatry 63, 1106-1112.
33. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J, International Treatment Refractory OCDC (2002). Treatment non-response in OCD: methodological issues and operational definitions. International Journal of Neuropsychopharmacology 5, 181-191.
34. Pauls DL, Alsobrook JP II, Goodman W, Rasmussen S, Leckman JF (1995). A family study of obsessive-compulsive disorder. American Journal of Psychiatry 152, 76-84.
35. Pogarell O, Hamann C, Popperl G, Juckel G, Chouker M, Zaudig M, Riedel M, Moller HJ, Hegerl U, Tatsch K (2003). Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biological Psychiatry 54, 1406-1413.
36. Praschak-Rieder N, Wilson AA, Hussey D, Carella A, Wei C, Ginovart N, Schwarz MJ, Zach J, Houle S, Meyer JH (2005). Effects of tryptophan depletion on the serotonin transporter in healthy humans. Biological Psychiatry 58, 825-830.
37. Rauch SL, Savage CR (1997). Neuroimaging and neuropsychology of the striatum. Bridging basic science and clinical practice. Psychiatric Clinics of North America 20, 741-768.
38. Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, Mundt A, Smoltczyk HU, Goldman D, Mann K, Reischl G, Machulla HJ, Bares R, Heinz A (2007). Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study. Journal of Neural Transmission 114, 1603-1609.
39. Selvaraj S, Turkheimer F, Rosso L, Faulkner P, Mouchlianitis E, Roiser JP, McGuire P, Cowen PJ, Howes O (2012). Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. Molecular Psychiatry 17, 1254-1260.
40. Stein DJ (2000). Neurobiology of the obsessive-compulsive spectrum disorders. Biological Psychiatry 47, 296-304.
41. Stengler-Wenzke K, Muller U, Angermeyer MC, Sabri O, Hesse S (2004). Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD). European Archives of Psychiatry and Clinical Neuroscience 254, 252-255.
42. Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, Ikoma Y, Tanada S, Suhara T (2006). A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology 185, 395-399.
43. Talbot PS, Frankle WG, Hwang DR, Huang Y, Suckow RF, Slifstein M, Abi-Dargham A, Laruelle M (2005). Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans. Synapse 55, 164-175.
44. van der Wee NJ, Stevens H, Hardeman JA, Mandl RC, Denys DA, van Megen HJ, Kahn RS, Westenberg HM (2004). Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]β-CIT SPECT. American Journal of Psychiatry 161, 2201-2206.
45. Vythilingum B, Cartwright C, Hollander E (2000). Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors. International Clinical Psychopharmacology 15 (Suppl. 2), S7-S13.
46. Wang Z, Maia TV, Marsh R, Colibazzi T, Gerber A, Peterson BS (2011). The neural circuits that generate tics in Tourettes syndrome. American Journal of Psychiatry 168, 1326-1337.
47. Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wickramaratne PJ (1994). The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. Journal of Clinical Psychiatry 55 (Suppl.), 5-10.